 Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline. AUTO1 has entered a pivotal trial for ALL and may achieve regulatory approval by 2022, while, for AUTO3, an outpatient cohort has been initiated in DLBCL. 